Dainippon Sumitomo

Latest Headlines

Latest Headlines

Intercept's much-hyped NASH drug misses the mark in Phase II

Intercept Pharmaceuticals' new drug for the pervasive liver disease NASH came up short in a Phase II trial in Japan, seeding some worries about an ongoing late-stage study designed to support future FDA approval.

PhIII flop for top Boston cancer stem cell program batters Dainippon Sumitomo

Over the long holiday weekend, Dainippon Sumitomo's shares took a beating--dropping 21% at one point, according to Bloomberg--as investors reacted to the news that BBI608 proved to be a dud in its most advanced trial for colorectal cancer.

Edison, Dainippon deepen deal with $50M up front and billions in biobucks

Japan's Dainippon Sumitomo Pharma has expanded its alliance with upstart Edison Pharmaceuticals, committing $50 million to jointly develop treatments for orphan diseases with nearly $4 billion more tied to down-the-road milestones.

Dainippon Sumitomo inks $545M-plus orphan drug R&D pact with Edison

Edison Pharmaceuticals shed its stealth mode and went public with a $545 million-plus collaboration deal with Japan's Dainippon Sumitomo that centers on its lead late-stage drug for rare diseases.

Intercept Pharma files for $75M IPO to back PhIII liver drug

Just days after rounding up $30 million in venture cash, New York-based Intercept Pharmaceuticals is boldly gambling that investors will cough up about $75 million to buy into a late-stage orphan drug for chronic liver disease. The biotech filed for an ambitious IPO, hoping it can avoid the price cuts that most other such development-stage biotech bids have been forced to endure in recent years. 

Nitto Denko, Dainippon begin Phase II for world's first transdermal antipsychotic

Nitto Denko and Dainippon Sumitomo have started a Phase II trial of a transdermal patch delivering Dainippon Sumitomo's antipsychotic Lonasen (blonanserin), which has been launched in Japan and South Korea.

Dainippon bags Boston Biomedical and cancer stem cell tech in $2.6B buyout

Boston Biomedical's focus on targeting cancer stem cells has paid off.

Chelsea Therapeutics reports positive efficacy results in PhII fibromyalgia study

Chelsea Therapeutics ($CHTP) has racked up some more positive efficacy data for its lead drug droxidopa, which is now up for review at the FDA. Investigators reported the drug spurred a statistically

Sunovion's inhaled steroid for allergies looks good in Ph3 amid FDA review

While the FDA reviews its application for approval of the experimental drug, Sunovion Pharmaceuticals revealed upbeat data from a major Phase III trial of its ciclesonide nasal aerosol against...

Intercept lands $315M Asian pact for liver disease drug

Japan's Dainippon Sumitomo is slapping down $15 million and promising up to $300 million more in milestones in exchange for the rights to Intercept Pharmaceuticals' late-stage liver disease drug in